Personal Genome Diagnostics' CancerSelect Enterprise Solution

Personal Genome Diagnostics has launched its CancerSelect Enterprise Solution for labs with next-generation sequencing capabilities that aim to conduct advanced cancer genetic testing for research applications.  CancerSelect ES provides a turnkey solution that includes the firm's CancerSelect gene panels, proprietary bioinformatics software, staff training, ongoing technical support, report generation, and panel updates. The two PGDx CancerSelect panels detect alterations in 88 and 203 well-characterized genes that are of high biologic importance in cancer, and were selected for their relevance to cancer-related drug targets and pathways, according to the company.